Instil Bio

Instil Bio, Inc. operates as a clinical-stage biopharmaceutical company, directing its efforts toward the development of cell therapies for the treatment of cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas. The foundation of Instil Bio's therapeutic approach is built upon tumor-infiltrating lymphocytes (TILs), a type of cancer immunotherapy. This involves harvesting a patient's own T cells that have infiltrated their tumor, expanding them to large numbers in a laboratory setting, and then infusing them back into the patient to attack the cancer. The company's lead product candidate is ITIL-168, which has been evaluated in a Phase 2 clinical trial for the treatment of advanced melanoma. Another product, ITIL-306, is in a Phase 1 trial for non-small cell lung cancer, ovarian cancer, and head and neck squamous cell carcinoma. Instil Bio's business model centers on the in-licensing, acquisition, and subsequent development of these novel therapeutic candidates to address significant unmet medical needs in oncology. The company has positioned itself in the competitive immuno-oncology market, targeting solid tumors, which represent a substantial area of need. Significant milestones for the company include its initial public offering (IPO) in March 2021, which raised approximately $368 million. This event provided substantial capital to advance its clinical pipeline. However, the company has faced challenges. In late 2022, Instil Bio announced a significant restructuring, which included pausing the development of its ITIL-168 program to extend its cash runway and discontinuing its phase 1 trial of ITIL-306. This strategic shift also involved a substantial reduction in its workforce as the company refocused its resources. As of early 2024, the company's focus remained on a strategic reprioritization of its pipeline and manufacturing operations. Keywords: cell therapy, oncology, biopharmaceutical, tumor-infiltrating lymphocytes, cancer immunotherapy, clinical-stage, solid tumors, melanoma, ITIL-168, immuno-oncology